Paul R. Fonteyne insider trades
Open-market stock purchases and sales by Paul R. Fonteyne, Unknown at Amylyx Pharmaceuticals, Inc, from SEC Form 4 filings since May 8, 2019.
Track record: 50% of 2 scored buys are up 5% or more since purchase, averaging 0%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 4, 2026 | AMLX Amylyx Pharmaceuticals, Inc | Bought (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | — |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | $369K |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | $980K |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | $357K |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | $404K |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | $385K |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | $1.6M |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc | Sold (not open market) | $344K |
| Jan 1, 2026 | APLS Apellis Pharmaceuticals, Inc | Bought (not open market) | — |
| Jan 1, 2026 | APLS Apellis Pharmaceuticals, Inc | Bought (not open market) | — |
Companies traded
- AMLX Amylyx Pharmaceuticals, Inc: 1 buy, last Jun 4, 2026
- APLS Apellis Pharmaceuticals, Inc: 1 buy, last May 14, 2026
- CVET Covetrus, Inc: 1 buy, last Oct 13, 2022
- GLS Gelesis Holdings, Inc: other filings, last May 6, 2022
- AMAG Amag Pharmaceuticals, Inc: other filings, last Nov 16, 2020
- TORC resTORbio, Inc: other filings, last Jun 3, 2020